Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About Aptinyx Inc.
Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. The company is headquartered in Evanston, Illinois and currently employs 12 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. The firm focuses on targeting and modulating N-methyl-D-aspartate receptors, (NMDArs), which are vital to the normal and effective function of the brain and nervous system. The firm's NYX-783 is in Phase 1 clinical development for the treatment of opioid use disorder (OUD), and in preclinical development for the treatment of alcohol use disorder. NYX-783 modulates NMDA receptors to increase glutamatergic activity in key regions and may act to enhance extinction learning and alleviate the emotional symptoms of opioid withdrawal. The firm's NMDAr modulator discovery platform builds on NMDAr biology. The platform has the potential to develop into a broad pipeline and product portfolio across an array of disorders of the brain and nervous system.
Industry: Pharmaceutical Preparations Peers: Elevation Oncology, Inc. Spyre Therapeutics, Inc. Avalo Therapeutics, Inc. Comera Life Sciences Holdings, Inc. GeoVax Labs, Inc. Marker Therapeutics, Inc. ORAGENICS INC TREVENA INC
